Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Cloughesy

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Radiology|June 30, 2009
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatmentWhitney B Pope, Hyun J Kim, Jing Huo, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2012
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patientsDavid A Reardon, Charles A Conrad, Timothy Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
The Oncologist|December 15, 2010
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN studyJames J Vredenburgh, Timothy Cloughesy, Meghna Samant, et al.
Journal of Neuro-Oncology|October 14, 2008
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasNicholas Butowski, Kathleen R Lamborn, Bee L Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed GlioblastomaCaroline Happold, Thierry Gorlia, Olivier Chinot, et al.
Neuro-Oncology|November 19, 2010
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumabMichael Prados, Timothy Cloughesy, Meghna Samant, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 7, 2017
Detection of immune responses after immunotherapy in glioblastoma using PET and MRIJoseph P Antonios, Horacio Soto, Richard G Everson, et al.
Neuro-Oncology|November 2, 2012
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiationSichen Li, Arthur P Chou, Weidong Chen, et al.
Nature Communications|November 27, 2021
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastomaAlexander H Lee, Lu Sun, Aaron Y Mochizuki, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Radiology|June 30, 2009
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatmentWhitney B Pope, Hyun J Kim, Jing Huo, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2012
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patientsDavid A Reardon, Charles A Conrad, Timothy Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastomaHenry S Friedman, Michael D Prados, Patrick Y Wen, et al.
The Oncologist|December 15, 2010
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN studyJames J Vredenburgh, Timothy Cloughesy, Meghna Samant, et al.
Journal of Neuro-Oncology|October 14, 2008
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasNicholas Butowski, Kathleen R Lamborn, Bee L Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed GlioblastomaCaroline Happold, Thierry Gorlia, Olivier Chinot, et al.
Neuro-Oncology|November 19, 2010
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumabMichael Prados, Timothy Cloughesy, Meghna Samant, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 7, 2017
Detection of immune responses after immunotherapy in glioblastoma using PET and MRIJoseph P Antonios, Horacio Soto, Richard G Everson, et al.
Neuro-Oncology|November 2, 2012
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiationSichen Li, Arthur P Chou, Weidong Chen, et al.
Nature Communications|November 27, 2021
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastomaAlexander H Lee, Lu Sun, Aaron Y Mochizuki, et al.
Pageof 10